



SUBMISSION OF A NEW PATENT APPLICATION

COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C.

JCS 511 U.S. PRO
09/225499
01/06/99

Sir: Transmitted herewith for filing is the patent application of
inventor, Roger M. Loria.

For: 5-Androstene-3 β ,17 α diol as an Inhibitor of Tumor Growth

Enclosed are
15 pages of specification, including the claims
1 page of abstract
Declaration and Power of Attorney
A Declaration claiming Small Entity status

Filing fee has been calculated as shown below:


Basic fee:	\$395.00
Total claims: 14	
There is no extra independent claim	
Total Fee:	\$395.00

If further fees are payable, the commissioner is authorized to
debit Deposit Account 08-1652 in the amount required to fully pay
all fees.

All correspondence regarding this application should be directed
to:

Glenna Hendricks
P. O. Box 2509
Fairfax, VA 22031-2509

Telephone: (703) 591-4470
Telefax (703) 591-4428

By 
Glenna Hendricks, Reg. No 32,535

APPLICATION FOR PATENT

Title: 5-ANDROSTENE 3 β ,17 α DIOL AS AN INHIBITOR OF TUMOR GROWTH

This application is a continuation of USSN 08/838,823 filed April 10, 1997, now pending.

Background of the Invention:

5

Field of the Invention:

This invention relates to the field of pharmaceuticals for tumor-inhibitory effects. The 5-androstene 3 β ,17 α diol (α AED), its esters and ethers, are taught herein to achieve tumor-inhibiting effect.

10

Description of Related Art:

Mifepristone (RU486) is used as a progesterone receptor antagonist (See U.S. Patent 4,386,085, which is incorporated herein by reference in its entirety) and has been shown to have use both as an abortifacient and has been found useful for treating steroid-dependent breast cancer.

15

Flutamide, which has been disclosed in U.S. patent 3,847,988 (which is incorporated herein by reference in its entirety) is an antiandrogen that has been used to treat prostatic cancer, usually in conjunction with estrogen.

20

U.S. Patent 2,521,586 to Levy, et al., teaches production of the 17-monobenzoate ester of androstene diol. No use of the 5-androstene 3 β , 17 α diol (α AED) is taught therein.

25

Peat, in U.S. Patent 4,628,052 teaches a genus which might, arguably, within the scope of the genus, encompass the α AED. However, all examples and all named compounds require a keto group. Hence, it is reasonable to conclude that the α AED is not intended therein.

30

Tindall, in U.S. Patent 2,845,381 teaches cosmetic compositions containing the α AED. No medicinal compositions appropriate for internal use or medicinal uses are suggested

therein.

U.S. Patent 4,882,322 to Johnson, et al. Teaches substituted 5-androstene 3 β ,17 β diol to regulate or inhibit the conversion of androgens to estrogens. The α AED is not taught therein.

5 Swartz, et al., in U. S. Patent 4,898,694 teaches a very large group of compounds which encompass substituted androstanediols. However, Schwartz does not suggest the α AED nor the esters and ethers claimed herein for any purpose.


10 Loria, in U.S. Patents 5,206,008, 5,277,907, 5,3876,583, 5,461,042 and 5,478,566 teaches that the 5-androstene 3 β ,17 β diol (β AED) and 5,-androstene 3 β ,7 β ,17 β triol (AET) enhance immune response, and also are useful for counteracting the untoward effects of irradiation and chemotherapy, and buffer 15 the anti-proliferative effects of hydrocortisone. None of these patents teaches or suggests use of α AED. As taught therein, the β AED is most effective if administered in such a manner that it contacts tissue of ectodermal origin.

20 **Summary of the Invention:**

The instant invention provides a means of accelerating cell aging and programmed cell death in tumor cells. The practice of the invention involves administration of 3 β ,17 α androstanetriol (which may be referred to in this application as either 17 α AED or simply α AED) and esters and ethers thereof.

25 **Description of the Invention:**

The instant invention relates to the use of 5-androstene 3 β ,17 α diol (herein referred to as α AED or 17 α AED), its esters and ethers, to inhibit growth and accelerate cell aging, induce 30 apoptosis and death of tumor cells as a means of treating malignancies. The active agents of the invention may also be used as contraceptives and abortifacients. The active agents are of the structure:



15 wherein R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR₂, wherein R₂ is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl. Any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized.

20 It has been found that these active agents, when administered as described herein, inhibit cell growth. The αAED is administered in sufficient dosages to provide a blood concentration of from 5 to 10,000 nM when given systemically. A more preferred blood or tissue fluid concentration is in the range of 10 to 10,000 nM. The dosage will vary with the type of cell to be inhibited. The method of administration will depend on the location of the target cells. Such means as parenteral or oral administration are also appropriate. The αAED may also be administered by applicator or in a spray to tissue during surgery. Compositions containing the active agents taught herein may be administered vaginally or rectally either by

instillation of a liquid composition or on supports such as sponges.

Other preferred methods of administration include buccal, sublingual, nasal or endotracheal routes. Sprays or mists may be useful for such administration. Furthermore, sprays may be useful for administration to the operative area during surgery. For example, sprays may be used to contact the peritoneal cavity or the thoracic cavity during surgery.

Compositions of the invention may also be administered to the intestinal mucosa by oral or rectal routes. Suppositories, solutions for use as retention enemas and creams or jellies are appropriate means for use in rectal administration.

Compositions of the invention may also be applied to the vaginal mucosa using creams, jellies suppositories or douching solutions. The compositions may be in the form of prophylactic vaginal preparations or may be used in lubricants on condoms. Jellies and creams may also be administered by application in a cervical diaphragm which, when in place, will provide for prolonged contact with the cervix.

For purposes of administration into an orifice of the body, the compositions of the invention may be administered via a flexible tube into the target site. As indicated previously, the compositions containing α AED may be administered as a douche or retention enema. Other target sites include the bladder, uterus, trachea, nasopharynx, sinus or (via the nasal passage) the pituitary.

The carrier system used in a given instance will depend on the mode of administration. The active agents are lipophilic compounds. Solvents and carriers for lipophilic steroids known in the art are appropriate for use in the compositions containing α AED or the esters and ethers of α AED. Examples of such carriers are glycols such as polypropylene glycol, polyethylene glycol, ethanol, DMSO and cyclodextrins (especially the amorphous cyclodextrins). Cyclodextrins will pass through the buccal mucosa into the circulation easily.

This method is particularly appropriate for administration as a means of avoiding intravenous administration while bypassing the liver. Other vehicles that should be considered include fatty acid esters of polyoxyethylene sorbitol (Tweens) or 5 sorbitan (Spans) for preparation of emulsions.

The compositions taught herein may be used to treat most neoplasms, including for, for example, use in treatment of neoplasms, including those of the blood-forming organs, the liver, pancreas, thyroid, adrenals, pituitary, ovaries, 10 testicles, breast, central nervous system (including brain, spinal column), bone, connective tissue, lungs, liver, the gastro-intestinal system, uterus, mucous membranes, mouth and tongue, the lining of the peritoneum, the lymphatics and sensory organs.

15 Materials and Methods:

The β AED, 17 beta-oestradiol and tamoxifen were obtained from Sigma Chemical Company (St. Louis, Missouri). The α AED and Flutamide were obtained from Steraloid, Inc. (Walton, New Hampshire) and Schering Corporation (Kenilworth, New Jersey), 20 respectively. All steroids except β AED were dissolved in ethanol. β AED was dissolved in DMSO:ETHOL (1:1 v/v). Stock solutions were filtered and kept at 4°C. For testing, stock solutions were diluted in media immediately before use. The final concentration of vehicle was always \leq 0.2% in all samples, and this concentration had no significant cytotoxic 25 effect on the human breast cell cancer cell line designated ZR-75-1 (American Type Culture Collection) as determined by trypan blue exclusion.

The ZR-75-1 cell line (passage 89) was obtained from the 30 American Type Culture Collection (Rockville, Maryland). The cells were cultured in RPMI-1640 medium containing 10% heat-inactivated fetal calf serum, 200 μ M L-glutamine, 10 NM HEPES, 1.5 U/ml penicillin, and 1.5 μ g/ml streptomycin in 5% CO₂ at 37°C. The cells were passaged twice weekly.

Cell Growth for testing:

Cells were first seeded at initial density of 1×10^5 cells per ml in quadruplicates in 24 multi-well flat bottom plates (Costar). Cells were then allowed to adhere and grow in phenol 5 red-free RPMI 64 media supplemented with 10 % heat-inactivated fetal calf serum (FCS), 200 μ M L-glutamine, 10 mM HEPES, 2.5 U/ml penicillin and 2.5 μ g/ml streptomycin in 5% CO₂ at 37°C. After 48 hours, four wells were sacrificed and counted to determine plating efficiency. In the remaining wells, medium 10 was removed by aspiration and cells in each well were exposed to the media containing the specified steroid. The controls containing only medium or medium with vehicle were also prepared. In all samples, medium was changed every 48 hours. At the pre-established time-point. Cells were removed by trypsinization and washed. Cell number and viability were 15 determined by trypan blue exclusion using a hemocytometer. Parallel cultures were also run to determine cell proliferation.

Cell Proliferation Assays:

For cell proliferation assays, cell suspensions were prepared by trypsinization of cells from cultures prepared in accord with methods described above. Cell viability was determined by trypan blue exclusion. The cells were then seeded in flat-bottom 96-well microtiter plates at a density of 2×10^3 cells/well and were allowed to rest for 48 hours in order to adhere. Non-adherent dead cells were removed by aspiration. Cells were then grown in media without phenol red. Some of the media contained supplements as indicated above. The active agents or vehicle control were added to the media. 20 The cells were then grown for six days. Media was changed on the samples every 48 hours. On day 6, cells were pulsed with 1 μ Ci [³J]-thymidine for the last 6 hours of incubation before 25 harvesting onto glass filter using a HPD cell harvester (Cambridge Technology, Watertown, Massachusetts) and counted on a KLB scintillation counter.

Initial tests were carried out to determine the optimal (maximal) dose of α AED required to inhibit growth of the ZR-75-1 cells in in vitro as determined by tritiated thymidine incorporation. At concentration of 12.5 η M or greater, the α AED significantly inhibited the growth of ZR-75-1 cells, and this anti-proliferative effect occurred in a dose and time-dependent manner at half-maximal (50 η M) and maximal dose (100 η M) levels. To ensure that inhibition was not due to cytotoxicity, cell count and viability were assessed by trypan blue exclusion. The addition of the 17 α AED was not toxic to the cells. As opposed to α AED, the β AED (an epimere) alone at 100 η M concentrations did not have any antiproliferative effect on the growth of the ZR-75-1 cells.

Example 1:

ZR-75-1 cells (2×10^3) were treated as described above over a six day period with differing concentrations of α AED or with vehicle-only cultures. The medium was changed every 48 hours. Cells were pulsed with 3 H-thymidine for the last six hours of incubation.

Results showed increasing proliferation at 6.25 η M with decreasing cell proliferation at 12.5 η M and marked decrease at concentrations of 50 η M concentrations.

Example 2:

Cells were treated as in Example 1, except that in some samples a combination of 17 α AED and β AED were used. The concentration of the α AED varied while the concentration of the β AED in the samples containing the combination of agents remained constant at 2.5 η M. Cells were pulsed with 3 H-thymidine for the last six hours.

The proliferation of cells in cultures containing α AED in the presence of β AED showed decreased proliferation at all concentrations of α AED.

Example 3:

Effects of α AED on growth of ZR-75-1 cells in the presence of estradiol was studied. Cells treated with increasing

concentration of α AED in the presence or absence of 1 η M concentration of estradiol over a 6 day period were studied. Cells were treated with increasing concentration of α AED in the presence of 1 η M concentration of estradiol over a 6 day period, with medium changed every 48 hours. Cells were pulsed with 3 H-thymidine for the last six hours of incubation. At higher doses of α AED the α AED suppressed proliferation even in the presence of estradiol. Hence, estradiol can not effectively overcome the antiproliferative activity of α AED on this human breast cancer cell line. (This indicates that α AED may be useful in prevention of estrogen-dependent breast cancer.)

Example 4:

Effects of α AED on growth of ZR-75-1 cells in the presence of Flutamide, an antiandrogen, were studied using the process of Example 3 except that estradiol was replaced with Flutamide. The administration of α AED with antiandrogens, especially in treating estrogen-dependent malignancies such as breast cancer, should be considered particularly advantageous treatment option.

Example 5:

Example 5 was again studied in the presence of RU486. Again, it was shown that at effective concentrations it was possible to lower dosage of RU486 in the presence of effective amounts of .1 μ l concentrations of α AED with 0.5 μ M concentration of RU486 there was synergistic action to decrease proliferation of cells. This synergism was shown to be even greater at RU486 concentrations of 1 μ M. This combination of active agents would be especially useful for treatment of tumors which are dependent on estrogen or progesterone.

Example 6:

Preparation for instillation:

Ingredient	%w/w
α AED	0.01%
polypropylene glycol	13.0 %
Water	86.5%

Example 7:

Preparation for intravenous injection:

Ingredient	Amount
α AED	1 mg.
Ethanol	5 ml.
Phosphate buffered saline	Add to 1000 ml.

Example 8:

Effect of α AED on growth of lymphoid neoplasm (P388D1 cells obtained from the American Type Culture Collection) in the presence of RU486 at concentration of 0.5 μ M and 1.0 μ M was studied in accord with the methods described above. It was found that the use of α AED in combination with RU486 resulted in increased effectiveness over use of one agent.

Example 9:

Effects of α AED at doses of 50 μ M and 100 μ M doses on murine macrophage myeloma cells (RAW 264.7, obtained from the American Type Culture Collection) was studied. At both 50 μ M and 100 μ M levels there was significant inhibition of proliferation.

Example 10:

Preparation for instillation into the bladder for treatment of bladder cancer:

Ingredient	Amount
α AED	10 mg
DMSO	100 ml
half-normal saline	900 ml.

Example 11:

Water, 100 ml, is mixed with 7 g. β -hydroxypropyl cyclo-dextrin and 1 mg α AED. Fill ampules with the solution and

sterilize. This preparation may be added to solutions for administration to the mucosa, for oral administration, or for parenteral administration.

Example 12:

5 The cyclodextrin/αAED preparation is prepared as above. The material is freeze-dried and placed in sterile ampules. The resulting powder may be placed in vials. The contents of the vials may then be snorted into the nasal cavity. It is also appropriate to dissolve the contents of the vials and
10 place in solution for intravenous or topical application, including for infusion into a wound site. It may also be applied by spraying or sponging into the operative site such as the abdominal or thoracic cavity.

Example 13:

15 The preparation of Example 12 is diluted with 100 ml water. The preparation is sprayed into the abdominal cavity during and after removal of a colon malignancy.

20 αAED may be delivered to or through the skin by any means, including subcutaneous or intradermal injection or topical application. One means of topical application is the use of skin patches impregnated with the active agent. This means of delivery is advantageous since it is non-invasive and easily administered by relatively unskilled care providers.

Example 14:

25 Capsules of a formulation of αAED for oral administration is prepared by mixing 2 mg. αAED, 15 mg. Starch and 5 mg. Magnesium stearate. The capsules are administered twice a day to achieve a daily dosage of 1-50 mg./da.

30 The compositions of the invention may be administered intrathecally either at the spinal level or into the cisterna magna.

35 When αAED, its esters or ethers are administered orally, it is necessary that the active agents be protected from destruction and absorption in the upper gastro-intestinal tract. The active agents are most effective when the period of

exposure to the mucosa of the intestinal tract is increased. Hence use of capsules containing the active agents in formulations that effect slow release in the intestine are appropriate.

5 The active agents may also be used in veterinary medicine for treatment of animals suffering from tumors. For purposes of such treatment, the α AED may be added to the chow of the animals.

10 The sterile solutions may be administered to the lung either by bronchoscopic means or by mist which may be under pressure.

15 Patched for administration of α AED may be formulated as adhesive patches containing the active agent. For example, the patch may be a discoid in which a pressure-sensitive silicone adhesive matrix containing the active agent may be covered with a non-permeable backing. The discoid may either contain the active agent in the adhesive or may be attached to a support made of material such as polyurethane foam or gauze that will hold the active agent. When patches are used in treating animals, the area must be shaved or plucked. In all instances, the area to which the patch is applied should be cleaned carefully before application.

20 **Example 15:**

25 A patch composed of trilaminate of an adhesive matrix sandwiched between a non-permeable backing and a protective covering layer is prepared in the following manner:

30 To a pressure-sensitive silicone adhesive composition BIOPSA™ q7-2920 (Dow Corning Corporation, Midland, Michigan, U.S.A.) In cyclohexane (50% w/v) is added sufficient α AED to provide a .5% α AED composition. The adhesive is applied to a polyester film to provide in successive layers about 2 mg. Of active agent per cm^2 . Patches should be covered with a protective layer which will be removed before application.

35 Patches may be prepared containing permeation enhancers such as cyclodextrin, butylated hydroxyanisole, or butylated


hydroxytoluene.

The active agents may be administered to the mucosa of oral, pharyngeal or nasal cavity by tablet or lozenge.

The antiproliferative agents taught herein may be used in conjunction with other active agents such as vinca alkaloids, nucleic acid inhibitors, platinum agents, interleukin-2, interferons, alkylating agents, antimetabolites, corticosteroids, DNA intercalating agents, anthracyclines and ureas. Examples of specific agents, in addition to those exemplified herein, include hydroxyurea, 5-fluorouracil, anthramycin, asparaginase, bleomycin, dactinomycin, dacabazine, cytarabine, busulfan, thiotepa, lomustine, mechlorethamine, cyclophosphamide, melphalan, mechlorethamine, chlorambucil, carmustine, 6-thioguanine, methotrexate, etc.

WHAT WE CLAIM IS:

5 1. A method of accelerating cell aging and programmed cell death by administering a composition containing a cell aging accelerating effective amount of a compound of the formula:




15 wherein either R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR₂, wherein R₂ is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl, and any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, in a pharmaceutically acceptable carrier.

20

25

2. A composition of matter comprising a cell aging and programmed cell death accelerating effective amount of α AED or an ester or ether thereof of the formula:



15
wherein R may be H, alkenyl of 2-8 carbons, alkyl of 1-8 carbons, phenylalkyl of 1-4 carbons, phenyl or COR_2 , wherein R_2 is H; alkyl of 1-8 carbons, alkenyl of 2-8 carbons, phenylalkyl wherein the alkyl has 1-4 carbons (including benzyl) or phenyl, and any phenyl moiety may have up to three substituents chosen from among hydroxy, carboxy of 1-4 carbons, halo, alkoxy of 1-4 carbons, alkyl of 1-4 carbons, or alkenyl of 2-4 carbons and wherein any alkyl may be a straight chain, branched chain, or the alkyl may be wholly or partially cyclized, in a form appropriate for oral administration.

20

25

3. A composition of claim 2 which is a tablet.

4. A composition of claim 2 wherein the composition is in the form of a capsule.

5. A composition of claim 2 wherein the composition is a liquid.

30

6. A composition of matter comprising a cell aging and programmed cell death accelerating effective amount of α AED in a cyclodextrin inclusion complex.

35

7. A method of claim 1 wherein the active agent is administered orally.

8. A method of claim 1 wherein the active agent is administered parenterally.

5

9. A method of claim 1 wherein the active agent is administered as a patch.

10. A method of claim 1 wherein the active agent is applied to mucosal tissue.

15

11. A method of claim 10 wherein the active agent is administered rectally.

12. A method of claim 10 wherein the active agent is administered vaginally.

20

13. A method of claim 10 wherein the active agent is applied as a spray or mist.

14. A method of claim 1 wherein the active agent is applied to the site of the tumor or tumor bed.

25

ABSTRACT

The instant application provides means of accelerating cell aging and programed cell death in tumor cells by administration of $3\beta,17\alpha$ androstenediol (α AED) or its ethers or esters.

DECLARATION AND POWER OF ATTORNEY

As below named inventor, I hereby declare that:

I believe I am the original, sole and first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled :"5-androstone-3 β ,17 α -Diol as an Inhibitor of Tumor Growth", the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37 CFR 1.56(a).

I (We) hereby claim the benefit of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. 112, my (our) acknowledge the duty to disclose material information as defined in 37 CFR 1.56(a) which occurred between the filing date of the prior application and the filing date of this application:

USSN 08/838,823 Filing date: APRIL 10, 1997 Status: pending

I hereby appoint the following attorneys and agents, with full power of substitution, association, and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Glenna Hendricks, Reg. No. 32,535

Address all telephone calls to Dr. Stephen Gates or Glenna Hendricks. Please address all correspondence to:

Glenna Hendricks
P.O. Box 2509
Fairfax, VA 22031-2509 Telephone (703) 591-4470

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Roger M. Loria

Dr. Roger M. Loria
Inventor's signature

JAN 06, 1998
date

Home Address: 3219 Brook Rd, Richmond, VA 23227-4803
which is also a mailing address

Citizen of the United States

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Roger M. Loria

Entitled: 5-Androstan-3 β ,17 α diol as an Inhibitor of Tumor Growth

Filed Herewith

DECLARATION CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) &
1.27(b) INDEPENDENT INVENTOR

As the below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office regarding the invention entitled 5-Androstan-3 β ,17 α diol as an Inhibitor of Tumor Growth filed herewith.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9 (c) if that person had made the invention, or any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9 (e).

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that those statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Roger M. Loria
Inventor

Dr. Roger M. Loria
Inventor's signature

Jan 06, 1999
date

3219 Brook Road, Richmond, VA 23227
Address